270 related articles for article (PubMed ID: 12163455)
1. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
3. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
[TBL] [Abstract][Full Text] [Related]
4. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjögren's syndrome.
Saegusa K; Ishimaru N; Yanagi K; Mishima K; Arakaki R; Suda T; Saito I; Hayashi Y
J Immunol; 2002 Jul; 169(2):1050-7. PubMed ID: 12097413
[TBL] [Abstract][Full Text] [Related]
5. Autoantigens and Sjögren syndrome.
Toda I
Cornea; 2002 Mar; 21(2 Suppl 1):S13-6. PubMed ID: 11995803
[TBL] [Abstract][Full Text] [Related]
6. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.
Yanagi K; Ishimaru N; Haneji N; Saegusa K; Saito I; Hayashi Y
Eur J Immunol; 1998 Oct; 28(10):3336-45. PubMed ID: 9808203
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.
Meng Z; Klinngam W; Edman MC; Hamm-Alvarez SF
PLoS One; 2017; 12(9):e0184781. PubMed ID: 28902875
[TBL] [Abstract][Full Text] [Related]
9. Autoantigen-specific CD4+CD28low T cell subset prevents autoimmune exocrinopathy in murine Sjögren's syndrome.
Saegusa K; Ishimaru N; Yanagi K; Haneji N; Nishino M; Azuma M; Saito I; Hayashi Y
J Immunol; 2000 Aug; 165(4):2251-7. PubMed ID: 10925313
[TBL] [Abstract][Full Text] [Related]
10. Mucosal administration of alpha-fodrin inhibits experimental Sjögren's syndrome autoimmunity.
He J; Zhao J; Li Z
Arthritis Res Ther; 2008; 10(2):R44. PubMed ID: 18419828
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis for autoantigen presentation and T cell activation.
Mircheff AK; Gierow JP; Wood RL; Akashi RH; Hofman FM
Adv Exp Med Biol; 1994; 350():651-4. PubMed ID: 8030550
[No Abstract] [Full Text] [Related]
12. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
13. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
14. MHC class II molecules, cathepsins, and La/SSB proteins in lacrimal acinar cell endomembranes.
Yang T; Zeng H; Zhang J; Okamoto CT; Warren DW; Wood RL; Bachmann M; Mircheff AK
Am J Physiol; 1999 Nov; 277(5):C994-C1007. PubMed ID: 10564093
[TBL] [Abstract][Full Text] [Related]
15. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome.
Haneji N; Nakamura T; Takio K; Yanagi K; Higashiyama H; Saito I; Noji S; Sugino H; Hayashi Y
Science; 1997 Apr; 276(5312):604-7. PubMed ID: 9110981
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of neonatal tolerance induced in an animal model for primary Sjögren's syndrome by intravenous administration of autoantigen.
Saegusa K; Ishimaru N; Haneji N; Yanagi K; Yoneda T; Saito I; Hayashi Y
Scand J Immunol; 2000 Sep; 52(3):264-70. PubMed ID: 10972902
[TBL] [Abstract][Full Text] [Related]
17. The role of caspase cascade on the development of primary Sjögren's syndrome.
Hayashi Y; Arakaki R; Ishimaru N
J Med Invest; 2003 Feb; 50(1-2):32-8. PubMed ID: 12630566
[TBL] [Abstract][Full Text] [Related]
18. Novel fragments of the Sjögren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death.
Nagaraju K; Cox A; Casciola-Rosen L; Rosen A
Arthritis Rheum; 2001 Oct; 44(10):2376-86. PubMed ID: 11665980
[TBL] [Abstract][Full Text] [Related]
19. Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome.
Inoue H; Tsubota K; Ono M; Kizu Y; Mizuno F; Takada K; Yamada K; Yanagi K; Hayashi Y; Saito I
J Immunol; 2001 May; 166(9):5801-9. PubMed ID: 11313424
[TBL] [Abstract][Full Text] [Related]
20. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]